pharmaphorum
DECEMBER 15, 2022
Ofev (nintedanib) has been recommended since 2015 for NHS use in IPF patients who have a forced vital capacity (FVC) value of 50% to 80% of normal, but will now be an option for people with less severe disease, i.e. an FVC of more than 80%.
European Pharmaceutical Review
JANUARY 18, 2024
Comparatively, in 2015, GlobalData’s research expected that sales of therapies for Gaucher disease will reach $1.16 billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). Gaucher disease market On the other hand, treatments for Gaucher disease, another key market, is expected to reach $1.3
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 19, 2022
FDA highlighted that over three quarters of new patents in the Orange Book between 2005 and 2015 were assigned to existing drugs. Patent Protection of Pharmacologically Active Metabolites: Theoretical and Technological Analysis on the Jurisprudence of Four Regions. Method for detecting genotoxic impurities in tenofovir. 2020-02-24.
European Pharmaceutical Review
MARCH 11, 2024
In fact, a study published in 2023 in The Lancet HIV revealed that women and men with HIV at age 40 had an average of 39 and 37 years of life left, respectively – only a few years less than that of the general population – if they started antiretroviral therapy (ART) after 2015. World Health Organization. The Global Health Observatory.
pharmaphorum
JANUARY 16, 2023
Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. And all are predominantly prevented or treated with medicines that are decades old.
European Pharmaceutical Review
JANUARY 31, 2025
Back in 2015, in the first IQVIA report 6 and prompted by Commissioner Tajanis initiative, 7 efforts were made by stakeholders to design a unifying methodology to best define and represent the evolution of access to biosimilar medicines and biosimilar competition dynamics. She holds a MSc in Pharmacology. References 1.
European Pharmaceutical Review
FEBRUARY 14, 2024
Firstly, the pharmacological response to LBPs does not follow traditional pharmacokinetic principles. 2015; 69(1):381–403 5. Despite the recent focus, LBPs of defined compositions are yet to be approved for commercialisation for any target indication. Leveraging Quorum Sensing to Manipulate Microbial Dynamics. 2021; 19:100306 4.
Expert insights. Personalized for you.
105 
Let's personalize your content